相关实验视频
Updated: May 9, 2025

05:57
Fat Preference: A Novel Model of Eating Behavior in Rats
Published on: June 27, 2014
13.1K
用于治疗儿童肥胖症的GLP-1受体激动剂:行为健康考虑
Grace B Jhe1,2,3, Amy Egbert4, Carolyn E Ievers-Landis5,6
1Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, MA, USA.
Childhood obesity (Print)
|April 30, 2025
概括
葡萄糖类-1受体激动剂 (GLP-1s) 越来越多地用于青少年体重管理,但行为健康指导是有限的. 进一步的研究和临床评估对于安全使用和青少年的最佳心理社会结果至关重要.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 青少年医学 青少年医学
- 行为健康 行为健康
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1) 的使用正在迅速增加,用于青少年体重管理 (12-18岁).
- 对于使用GLP-1治疗的青少年的行为健康考虑,存在有限的指导.
- 接受GLP-1的青少年可能容易受到肥胖,并发症和药物副作用的心理社会影响.
研究的目的:
- 为了讨论青少年的行为和心理社会因素,他们为体重管理处方了GLP-1.
- 审查关于GLP-1在儿科肥胖症中的使用及其对心理社会功能影响的现有文献.
- 激发讨论,研究和临床创新,以促进该群体的最佳实践.
主要方法:
- 对关于GLP-1用于儿科肥胖症的有限和正在发展的文献的审查.
- 评估心理社会功能和健康行为参与的关键方面.
- 视角作品综合当前的知识,并识别研究差距.
主要成果:
- 目前关于GLP-1s对青少年心理社会功能的具体影响的研究很少.
- 临床实践应评估饮食障碍,情绪不稳定,心理社会功能,生活质量,社会支持,健康行为和愿意改变.
- 在整个GLP-1治疗过程中,持续的查和监测至关重要.
结论:
- 呼吁开展研究和临床创新,以解决GLP-1在青少年中的心理社会影响.
- 查和监测是确保安全有效的GLP-1治疗的关键.
- 优化心理社会结果需要对使用GLP-1s治疗肥胖症的年轻人采取全面的方法.
相关概念视频
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Hormonal Regulation
42.9K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
42.9K
Oral Hypoglycemic Agents: Glinides
109
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
109
Oral Hypoglycemic Agents: Biguanides and Glitazones
133
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
133
Regulation of Food Intake
144
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
144
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117

